



Date: November 22, 2017

Sydney, Australia

ASX: NOX

**Noxopharm
Limited**

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operations Office:

Suite 3 Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive
Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

NOXOPHARM 2017 ANNUAL GENERAL MEETING WEBCAST

Noxopharm Limited (ASX: NOX) invites shareholders to the 2017 AGM to be held on **Monday, November 27th at 2pm** at the Sydney Sofitel Wentworth Hotel, Adelaide Room, Level 4, 61-101 Phillip St, Sydney.

For those unable to attend the meeting in person, shareholders may register to join a live webcast of the Meeting's presentations and Questions and Answers. The slides of the corporate presentations, which will include updates on the Company's Clinical Trial and Research and Development programs, will be released to the market by the ASX on the morning of the AGM. Questions for the AGM can be submitted to: info@noxopharm.com

A copy of the recorded webcast is expected to be released to the market and posted on the Noxopharm website the following day.

Please note the webcast is not a venue for voting.

To register for the AGM webcast, please visit:

<https://fnn.webex.com/fnn/onstage/g.php?MTID=e0310fc66e40ebab9fb805ad456791db9>

To view a copy of the 2017 Notice of Annual General Meeting, please follow this link: http://www.noxopharm.com/irm/PDF/1364_1/NoticeofAnnualGeneralMeetingProxyForm

.....

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs that are held by subsidiary company, Nyrada, Inc.

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au